A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

  1. Argilés, G.
  2. Mulet, N.
  3. Valladares-Ayerbes, M.
  4. Viéitez, J.M.
  5. Grávalos, C.
  6. García-Alfonso, P.
  7. Santos, C.
  8. Tobeña, M.
  9. García-Paredes, B.
  10. Benavides, M.
  11. Cano, M.T.
  12. Loupakis, F.
  13. Rodríguez-Garrote, M.
  14. Rivera, F.
  15. Goldberg, R.M.
  16. Cremolini, C.
  17. Bennouna, J.
  18. Ciardiello, F.
  19. Tabernero, J.M.
  20. Aranda, E.
  21. Tabernero, J.
  22. Falcone, A.
  23. Goldberg, R.
  24. Argilés, null
  25. Tabernero, J.
  26. Limón, M.L.
  27. Valladares, M.
  28. Jiménez, P.
  29. Vieitez, J.M.
  30. Grávalos, C.
  31. García-Alfonso, P.
  32. Santos, C.
  33. Páez, D.
  34. Sastre, J.
  35. Benavides, M.
  36. Aranda, E.
  37. Cano, M.T.
  38. Loupakis, F.
  39. Rguez Garrote, M.
  40. Guillén, C.
  41. Rivera, M.F.
  42. Safont, J.
  43. Hiret, S.
  44. Bennouna, J.
  45. Pannier, D.
  46. Malka, D.
  47. Falcone, A.
  48. Cremolini, C.
  49. Show all authors +
Journal:
European Journal of Cancer

ISSN: 1879-0852,  0959-8049

Year of publication: 2022

Volume: 177

Pages: 154-163

Type: Article

DOI: 10.1016/J.EJCA.2022.09.037 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus